Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Status:
Withdrawn
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine that Gemcitabine(GEM) plus oxaliplatin(OXA) (GEMOX)
is superior to Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) in prolonging
progression-free survival（PFS） in patients with Advanced Hepatocellular Carcinoma.